SrasV1, Ncbi, Merge, bibRecord, 001444

Oligonucleotide-based antiviral strategies.

Identifieur interne : 001444 ( Ncbi/Merge ); précédent : 001443; suivant : 001445

Oligonucleotide-based antiviral strategies.

Auteurs : S. Schubert [Allemagne] ; J. Kurreck

Source :

Handbook of experimental pharmacology [ 0171-2004 ] ; 2006.

RBID : pubmed:16594620

Descripteurs français

KwdFr :
- ARN catalytique (pharmacologie), ARN catalytique (usage thérapeutique), Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Humains, Maladies virales (traitement médicamenteux), Maladies virales (virologie), Oligonucléotides (pharmacologie), Oligonucléotides (usage thérapeutique), Oligonucléotides antisens (pharmacologie), Oligonucléotides antisens (usage thérapeutique), Petit ARN interférent (pharmacologie), Petit ARN interférent (usage thérapeutique).
MESH :
- pharmacologie : ARN catalytique, Antiviraux, Oligonucléotides, Oligonucléotides antisens, Petit ARN interférent.
- traitement médicamenteux : Maladies virales.
- usage thérapeutique : ARN catalytique, Antiviraux, Oligonucléotides, Oligonucléotides antisens, Petit ARN interférent.
- virologie : Maladies virales.
- Animaux, Humains.

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Humans, Oligonucleotides (pharmacology), Oligonucleotides (therapeutic use), Oligonucleotides, Antisense (pharmacology), Oligonucleotides, Antisense (therapeutic use), RNA, Catalytic (pharmacology), RNA, Catalytic (therapeutic use), RNA, Small Interfering (pharmacology), RNA, Small Interfering (therapeutic use), Virus Diseases (drug therapy), Virus Diseases (virology).
MESH :
- chemical , pharmacology : Antiviral Agents, Oligonucleotides, Oligonucleotides, Antisense, RNA, Catalytic, RNA, Small Interfering.
- chemical , therapeutic use : Antiviral Agents, Oligonucleotides, Oligonucleotides, Antisense, RNA, Catalytic, RNA, Small Interfering.
- drug therapy : Virus Diseases.
- virology : Virus Diseases.
- Animals, Humans.

Abstract

In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.

DOI: 10.1007/3-540-27262-3_13
PubMed: 16594620

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002287
to stream PubMed, to step Curation: 002287
to stream PubMed, to step Checkpoint: 002080

Links to Exploration step

pubmed:16594620

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oligonucleotide-based antiviral strategies.</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S" last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J" last="Kurreck">J. Kurreck</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16594620</idno>
<idno type="pmid">16594620</idno>
<idno type="doi">10.1007/3-540-27262-3_13</idno>
<idno type="wicri:Area/PubMed/Corpus">002287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002287</idno>
<idno type="wicri:Area/PubMed/Curation">002287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002287</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002080</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002080</idno>
<idno type="wicri:Area/Ncbi/Merge">001444</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Oligonucleotide-based antiviral strategies.</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S" last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J" last="Kurreck">J. Kurreck</name>
</author>
</analytic>
<series><title level="j">Handbook of experimental pharmacology</title>
<idno type="ISSN">0171-2004</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Humans</term>
<term>Oligonucleotides (pharmacology)</term>
<term>Oligonucleotides (therapeutic use)</term>
<term>Oligonucleotides, Antisense (pharmacology)</term>
<term>Oligonucleotides, Antisense (therapeutic use)</term>
<term>RNA, Catalytic (pharmacology)</term>
<term>RNA, Catalytic (therapeutic use)</term>
<term>RNA, Small Interfering (pharmacology)</term>
<term>RNA, Small Interfering (therapeutic use)</term>
<term>Virus Diseases (drug therapy)</term>
<term>Virus Diseases (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN catalytique (pharmacologie)</term>
<term>ARN catalytique (usage thérapeutique)</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Humains</term>
<term>Maladies virales (traitement médicamenteux)</term>
<term>Maladies virales (virologie)</term>
<term>Oligonucléotides (pharmacologie)</term>
<term>Oligonucléotides (usage thérapeutique)</term>
<term>Oligonucléotides antisens (pharmacologie)</term>
<term>Oligonucléotides antisens (usage thérapeutique)</term>
<term>Petit ARN interférent (pharmacologie)</term>
<term>Petit ARN interférent (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Oligonucleotides</term>
<term>Oligonucleotides, Antisense</term>
<term>RNA, Catalytic</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Oligonucleotides</term>
<term>Oligonucleotides, Antisense</term>
<term>RNA, Catalytic</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>ARN catalytique</term>
<term>Antiviraux</term>
<term>Oligonucléotides</term>
<term>Oligonucléotides antisens</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>ARN catalytique</term>
<term>Antiviraux</term>
<term>Oligonucléotides</term>
<term>Oligonucléotides antisens</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16594620</PMID>
<DateCompleted><Year>2006</Year>
<Month>04</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0171-2004</ISSN>
<JournalIssue CitedMedium="Print"><Issue>173</Issue>
<PubDate><Year>2006</Year>
</PubDate>
</JournalIssue>
<Title>Handbook of experimental pharmacology</Title>
<ISOAbbreviation>Handb Exp Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Oligonucleotide-based antiviral strategies.</ArticleTitle>
<Pagination><MedlinePgn>261-87</MedlinePgn>
</Pagination>
<Abstract><AbstractText>In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schubert</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kurreck</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Handb Exp Pharmacol</MedlineTA>
<NlmUniqueID>7902231</NlmUniqueID>
<ISSNLinking>0171-2004</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016337">RNA, Catalytic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016337" MajorTopicYN="N">RNA, Catalytic</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>125</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16594620</ArticleId>
<ArticleId IdType="doi">10.1007/3-540-27262-3_13</ArticleId>
<ArticleId IdType="pmc">PMC7120703</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Virus Res. 2004 Jun 1;102(1):19-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15068876</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14769924</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2002 Jul 11;418(6894):222-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12110898</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Sep 16;431(7006):343-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15372041</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Circulation. 2003 Jun 10;107(22):2793-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12771005</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Nov;77(21):11531-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14557638</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Ther. 2002 Dec;6(6):770-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12498773</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 2005 May 13;348(4):883-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15843020</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10802-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1438280</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2002 Jul 25;418(6896):435-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12087358</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Trends Pharmacol Sci. 2004 Jan;25(1):22-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14723975</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Ther. 2003 Jul;8(1):62-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12842429</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2004 Mar 1;320(1):135-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15003869</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2004 Oct 15;306(5695):392-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15486266</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8682-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15173583</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2005 Jan;11(1):56-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15619625</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Biotechnol. 2004 Mar;22(3):326-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14758366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Drug Discov Devel. 2004 Mar;7(2):188-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15603252</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Med. 2004;55:61-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14746510</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1978 Jan;75(1):280-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">75545</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Methods Mol Biol. 2004;252:545-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15017080</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Biochem. 2003 Apr;270(8):1628-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12694176</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nucleic Acids Res. 2002 May 1;30(9):1911-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11972327</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 Dec 17;578(3):285-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15589834</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Struct Mol Biol. 2004 Jul;11(7):599-606</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15170178</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2783-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12594341</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 Feb 27;560(1-3):69-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14988000</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochemistry. 2001 Dec 4;40(48):14645-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11724578</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Nov 11;432(7014):173-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15538359</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Biotechnol. 2003 Jun;21(6):635-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12754523</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 1998 Oct 2;436(2):233-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9781685</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mol Ther. 2004 Apr;9(4):596-606</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15093190</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Genet. 2003 May;4(5):346-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12728277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2001 May 24;411(6836):494-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11373684</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nucleic Acids Res. 2004 Jun 04;32(10):3101-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15181175</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Oncogene. 2004 Nov 1;23(51):8401-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15517022</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Sep 16;431(7006):371-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15372045</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Genes Dev. 2004 Mar 1;18(5):504-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15014042</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):773-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15640346</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2002 Jul 4;418(6893):38-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12097900</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8676-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15173599</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Genet. 2003 Jul;34(3):263-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12796781</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Mar;78(5):2601-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14963165</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nucleic Acids Res. 2003 Jun 15;31(12):3185-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12799446</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 May 27;100(11):6347-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12746500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2004 Jun 1;102(1):43-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15068879</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2005 Jan;11(1):50-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15619632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Rev Med Virol. 2004 Jan-Feb;14(1):47-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14716691</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2004 Jun 1;102(1):11-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15068875</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2002 Jul 25;418(6896):430-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12087357</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hepatology. 2000 Mar;31(3):769-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10706571</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2002 Jul;8(7):681-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12042777</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2718-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12594334</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2004 Apr;3(4):318-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15060527</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gastroenterology. 2003 Jul;125(1):9-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12851866</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Invest. 2000 Nov;106(10):1197-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11086019</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Biol. 2002 Aug 6;12(15):1301-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12176358</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2003 Mar;14(2):61-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12856917</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 2004 May 28;339(2):355-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15136038</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Ann N Y Acad Sci. 2003 Dec;1002:63-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14751823</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2002 Jul 11;418(6894):252-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12110902</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 1999 Sep 17;458(2):151-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10481055</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2004 Jun 1;102(1):27-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15068877</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Microbiol. 2004 Sep;2(9):704-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15372081</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 1998 Feb 19;391(6669):806-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9486653</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Oligonucleotides. 2003;13(6):539-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15025918</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochim Biophys Acta. 1999 Dec 10;1489(1):69-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10806998</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nucleic Acids Res. 2003 Aug 1;31(15):4417-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12888501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 1995 Oct 27;270(43):25702-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7592749</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Genet. 2004 May;5(5):355-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15143318</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Drug Targets Infect Disord. 2001 Aug;1(2):79-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12455406</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2002 Sep;76(18):9225-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12186906</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12518064</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell. 2003 Oct 17;115(2):209-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14567918</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nucleic Acids Res. 2003 Oct 15;31(20):5982-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14530446</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2004 Jan;61(1):49-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14670593</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Biotechnol. 2003 Mar;21(3):230-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12610564</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Methods Mol Biol. 2004;252:581-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15017082</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Biotechnol. 2004 Dec;22(12):1533-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15583662</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Drug Targets. 2004 Nov;5(8):667-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15578948</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gene. 1994 Nov 4;149(1):33-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7958986</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4262-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9113977</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell. 2003 Oct 17;115(2):199-208</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14567917</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 2005 Feb 18;346(2):457-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15670596</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Cell Biol. 2003 Sep;5(9):834-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12942087</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>BMC Microbiol. 2001;1:34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11801185</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Drug Deliv Rev. 2000 Oct 31;44(1):23-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11035195</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Biotechnol. 2003 Jun;21(6):639-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12740585</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2002 Apr 19;296(5567):550-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11910072</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gene Ther. 2005 Jan;12(1):5-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15496962</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2004 Jun 1;323(2):173-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15193913</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lab Invest. 2004 Jun;84(6):703-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15094712</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Struct Biol. 2003 Sep;10(9):708-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12881719</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):235-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12518066</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biomed Sci. 2003;10(6 Pt 1):607-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14576463</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antisense Nucleic Acid Drug Dev. 2000 Apr;10(2):117-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10805163</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Berlin</li>
</region>
<settlement><li>Berlin</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J" last="Kurreck">J. Kurreck</name>
</noCountry>
<country name="Allemagne"><region name="Berlin"><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S" last="Schubert">S. Schubert</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001444 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001444 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:16594620
   |texte=   Oligonucleotide-based antiviral strategies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:16594620" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Oligonucleotide-based antiviral strategies.

Oligonucleotide-based antiviral strategies.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki